License enables Dyadic Applied BioSolutions to expand genetic engineering capabilities Dublin, Ireland, and Jupiter FL, USA, 10 November 2025: ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions (‘Dyadic’), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today announced they have signed a non-exclusive agreement granting access to ERS’ foundational CRISPR/Cas9 patent portfolio. The license agreement enhances Dyadic’s ability to accelerate strain engineering and pathway optimization to enhance productivity, product quality, and innovation across its proprietary bioproduction platforms. John E. Milad, CEO, ERS Genomics, said: “Dyadic’s work illustrates how broad access